LAI Navigator
Intervals, oral overlap basics, and parent oral drug links. Verify product specifics in labeling.
Aripiprazole monohydrate
- Parent
- Aripiprazole
- Interval
- Monthly (q4wk)
- Oral overlap
- Yes — typically 14 days
- Site
- Deltoid or gluteal
- Consider 2‑week oral overlap after first injection
Aripiprazole lauroxil
- Parent
- Aripiprazole
- Interval
- q4–8wk (varies by strength)
- Oral overlap
- Yes — typically 21 days (unless using Initio loading)
- Site
- Deltoid or gluteal
- Initio option available for loading; see label
Paliperidone palmitate (PP1M/PP3M/PP6M)
- Parent
- Paliperidone
- Interval
- Monthly / q3mo / q6mo
- Oral overlap
- None after loading sequence
- Site
- Deltoid (initiation) or gluteal
- PP1M loading: Day 1 deltoid 234 mg, Day 8 deltoid 156 mg
- PP3M/PP6M require stabilization on PP1M/PP3M first
Risperidone microspheres
- Parent
- Risperidone
- Interval
- q2wk
- Oral overlap
- Yes — ~3 weeks due to lag
- Site
- Deltoid or gluteal
- 3‑week lag to therapeutic release; continue oral overlap
Haloperidol decanoate
- Parent
- Haloperidol
- Interval
- q4wk
- Oral overlap
- Consider short overlap during conversion
- Site
- Gluteal
- Typical conversion ~10–15× daily oral dose monthly; individualize
Fluphenazine decanoate
- Parent
- Fluphenazine
- Interval
- q2–4wk
- Oral overlap
- Consider during conversion
- Site
- Gluteal
- Approximate conversion often cited ~1.2× daily oral dose every 2–3 weeks; verify in label
Olanzapine pamoate
- Parent
- Olanzapine
- Interval
- q2–4wk
- Oral overlap
- Per label
- Site
- Gluteal
- Post‑injection observation required per labeling (PDSS)
Educational only — not medical advice. Verify administration and overlap specifics in official labeling.